Agreement - Astrazeneca Pharma India Ltd & Sun Pharmaceutical Industries Ltd

BSE: 524715 NSE:

and Sun Pharma partner to help patients living with Hyperkalaemia in India Under the agreement, both companies will promote, market & distribute SZC in India under different brand names; AstraZeneca will market SZC as Lokelma® whereas Sun Pharma will promote and distribute the therapy as Gimliand®. AstraZeneca will retain the intellectual property rights to SZC and hold the Marketing Authorisation along with the import license of the molecule